OCUGEN
Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
OCUGEN
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
2013-01-01
Address:
Malvern, Pennsylvania, United States
Country:
United States
Website Url:
http://www.ocugen.com
Total Employee:
11+
Status:
Active
Contact:
(720)859-3549
Total Funding:
190 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving
Similar Organizations
Nuvation Bio
Nuvation Bio is a biopharmaceutical company.
NuCana
NuCana is a clinical-stage biopharmaceutical company
Novaremed AG
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
Vidac Pharma
Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering
Vyriad
Vyriad is a clinical stage biopharmaceutical company.
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
MatriSys Bioscience
MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
MetrioPharm
MetrioPharm is a clinical stage pharmaceutical development company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Atom Bioscience & Pharmaceutical
Atom Bioscience is a clinical-stage biotechnology company.
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Aniluxx Biotechnology
Aniluxx Biotechnology is a development stage biopharmaceutical company
Aurealis Pharma
Aurealis Pharma is a biopharmaceutical company.
Avitide
Avitide develops affinity purification solutions for biopharmaceutical companies.
Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company.
EpimAb Biotherapeutics
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company.
BlueRock Therapeutics
It is a regenerative medicine company.
Biocytogen
Biopharmaceutical company.
BirchBioMed
BirchBioMed is a clinical-stage biomedical company.
Bond Biosciences
Bond Biosciences is a biopharmaceutical company
BiondVax
BiondVax is an innovative biopharmaceutical company.
BioQ Pharma
BioQ Pharma is a late stage specialty pharmaceutical company focused on developing.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Transcode Therapeutics
TransCode Therapeutics is a pre-clinical biopharmaceutical company.
Touchlight Genetics
Touchlight Genetics, a British bio-pharmaceutical company founded in 2007.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company.
UroGen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company.
Kangpu Biopharmaceuticals, Ltd.
Kangpu Bio-Pharma is a clinical stage company.
SELLAS Life Sciences
SELLAS Life Sciences is a late-stage biopharmaceutical company.
Strekin
Strekin AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SciClone Pharmaceuticals
SciClone Pharmaceuticals is a pharmaceutical company.
Soleno Therapeutics
Soleno Therapeutics is a clinical-stage biopharmaceutical company.
Semler Scientific
Semler Scientific is an emerging medical risk-assessment company.
Samsung Bioepis
Samsung Bioepis is a biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Humanetics Corporation
clinical stage pharmaceutical company.
HUTCHMED (China) Limited
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.
Inversago Pharma
Inversago Pharma is a specialized, preclinical-stage biotech company.
ImmunoBrain Checkpoint
ImmunoBrain Checkpoint is a biopharmaceutical company.
IconOVir Bio
IconOVir Bio is a preclinical-stage biotechnology company.
GENFIT
GENFIT is a late-stage biopharmaceutical company.
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals is a clinical stage biotech company.
OncoQuest
OncoQuest is a Edmonton-based biopharmaceutical company.
Ovid Therapeutics
Ovid Therapeutic's purpose is to solve intractable medical problems.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Opiant Pharmaceuticals
Opiant Pharmaceuticals is a specialty pharmaceutical company.
Cellenkos
Cellenkos is a clinical stage biotech company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Cassava Sciences
Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience.
CytoVac
Cytovac is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Peptidream
Peptidream is a biopharmaceutical company.
PharmaIN
PharmaIN is a development stage biopharmaceutical company,
PlasmaGen Biosciences
PlasmaGen Biosciences is a biopharmaceutical company .
Yisheng Biopharma
Yisheng Biopharma is a global, fully integrated bio-pharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2019-09-30 | Histogenics | Histogenics acquired by Ocugen | N/A |
Investors List
ROTH Capital Partners
ROTH Capital Partners investment in Post-IPO Equity - Ocugen
Abdi Ibrahim Pharmaceuticals
Abdi Ibrahim Pharmaceuticals investment in Series B - Ocugen
Lancaster Group
Lancaster Group investment in Series B - Ocugen
Frank Leo
Frank Leo investment in Series B - Ocugen
John Zhang
John Zhang investment in Series B - Ocugen
Bernhard Hampl
Bernhard Hampl investment in Series A - Ocugen
Ahsan M. Nasratullah
Ahsan M. Nasratullah investment in Series A - Ocugen
EB5 Life Sciences
EB5 Life Sciences investment in Series A - Ocugen
Key Employee Changes
Date | New article |
---|---|
2022-09-01 | Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer |
Official Site Inspections
http://www.ocugen.com Semrush global rank: 1.75 M Semrush visits lastest month: 13.48 K
- Host name: 68.121.245.35.bc.googleusercontent.com
- IP address: 35.245.121.68
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Ocugen" on Search Engine
Our People - Ocugen
Prior to co-founding Ocugen in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from “Big Pharma” to novel start-up biotechs. ... Rubin is the founder …See details»
Press Releases | Ocugen, Inc.
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»
Ocugen Clinical Trial Could Lead to Breakthrough One-Time …
NORTHAMPTON, Ma., Dec. 19, 2023 — The American Macular Degeneration Foundation received news that the first patient has been dosed in a safety and efficacy clinical trial of …See details»
Ocugen - Crunchbase Company Profile & Funding
Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes. Malvern, Pennsylvania, United States. 51-100. Post-IPO …See details»
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment …
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»
Ocugen | LinkedIn
About us. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and …See details»
Ocugen Provides Business Update with Fourth Quarter and Full …
MALVERN, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2
MALVERN, Pa., April 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel …See details»
Traditional gene therapies are uber-niche. Ocugen hopes to …
But a Pennsylvania-based biotech company Ocugen is hoping to change that paradigm by working on therapies that it calls “gene agnostic,” using a first-in-class modifier gene …See details»
Ocugen Announces OCU400—Modifier Gene Therapy—Phase …
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines that improve health and …See details»
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 …
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment …
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»
Ocugen - Contacts, Employees, Board Members, Advisors
About. Ocugen has 9 current employee profiles, including Vice President, Investor Relations and Operations Kelly Beck. Ocugen has 6 board members and advisors, including Frank …See details»
Can Ocugen Stock Keep Churning Higher? | The Motley Fool
Current Price. $1.39. Price as of April 29, 2024, 4:00 p.m. ET. This tiny biotech caught fire in 2024. Can it sustain the momentum? Since the start of the year, Ocugen ( OCGN …See details»
2024-05-03 | NDAQ:OCGN | Press Release | Ocugen Inc
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»
Ocugen - Funding, Financials, Valuation & Investors - Crunchbase
$206.5M. in funding over 6 rounds. Their latest funding was raised on May 24, 2023 from a Post-IPO Equity round. Which funding types raised the most money? Show. How much …See details»
2024-05-03 | NDAQ:OCGN | Press Release | Ocugen Inc
OCGN | 12 minutes ago. NEW YORK, May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. …See details»
Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine …
MALVERN, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing …See details»
2024-05-03 | NDAQ:OCGN | Press Release | Ocugen Inc
NEW YORK, May 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between …See details»
Ocugen, Inc. Announces Dosing Completion of Subjects with …
MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»